Business Context and Reporting Period
Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 31, 2025
Business Overview: The Company operates through two primary segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care products). The Company is a large accelerated filer with operations in the United States, Europe, and the Rest of World.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $1,060.3 | $1,002.8 | $3,027.3 | $2,877.0 |
| Gross Profit | $692.0 | $663.0 | $2,031.3 | $1,918.0 |
| Gross Margin | 65.3% | 66.1% | 67.1% | 66.7% |
| Operating Income | $175.7 | $192.5 | $542.5 | $507.3 |
| Net Income | $98.3 | $104.7 | $290.3 | $274.8 |
| Diluted EPS | $0.49 | $0.52 | $1.45 | $1.37 |
| Operating Cash Flow (9M) | $548.2 | $441.2 | - | - |
| Total Debt | $2,478.3 | - | - | - |
| Cash & Equivalents | $124.9 | - | - | - |
Note: Q3 2024 debt and cash figures are not explicitly provided in the summary text for direct comparison, though total debt decreased from $2,583.7 million at Oct 31, 2024 to $2,478.3 million at July 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5.7% in Q3 2025 and 5.2% for the nine-month period compared to the prior year. CooperVision sales grew 6% in Q3, driven by Toric and multifocal lenses. CooperSurgical sales grew 4% in Q3, aided by the obp Surgical acquisition.
- Profitability Decline: Operating income decreased 8.7% in Q3 2025 ($175.7M vs $192.5M). This was primarily due to a significant decline in CooperSurgical operating income, which turned to a loss of $4.2M from a profit of $41.3M in the prior year.
- Margin Pressure: Consolidated gross margin decreased to 65% in Q3 2025 from 66% in Q3 2024, driven by inventory write-offs related to a product line exit in CooperSurgical.
- Expense Increases: Selling, General, and Administrative (SGA) expenses rose 11% in Q3, and R&D expenses rose 14%, attributed to increased selling activities, salaries, and R&D project spend.
- Interest Expense: Interest expense decreased 11% in Q3 due to lower interest rates and lower average debt balances.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management remains optimistic about long-term prospects in contact lens and general healthcare markets. Growth is expected to be driven by market penetration of silicone hydrogel products and myopia management solutions. However, the outlook is tempered by global macroeconomic uncertainty, inflation, and trade barriers.
Unusual Items
- Product Line Exit: CooperSurgical recorded inventory and long-lived asset write-offs related to a product line exit, negatively impacting Q3 operating income and gross margin.
- Investment Loss: A $15.7 million loss on the disposal of a minority interest investment contributed to higher "Other expense, net" for the nine-month period.
- Share Repurchases: The Company repurchased 0.7 million shares in Q3 2025 for $52.2 million. $163.6 million remains authorized under the current program.
Risks and Contingencies
- Material Weakness in Internal Controls: The Company disclosed a material weakness in IT general controls for U.S. operations within the CooperSurgical segment related to ERP implementation, change management, and segregation of duties. Management is implementing remediation steps, but disclosure controls and procedures were deemed not effective as of July 31, 2025.
- Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes. A 10% change in exchange rates could impact operating income by approximately $26.2 million.
- Legal and Regulatory: Ongoing exposure to product liability, patent infringement, and regulatory changes (e.g., EU MDR/IVDR).
Investor Verification Checklist
- CooperSurgical Turnaround: Verify the timeline and financial impact of the product line exit write-offs and whether the segment can return to profitability.
- Internal Control Remediation: Monitor progress on remediation of the material weakness in IT general controls to ensure future financial reporting reliability.
- Acquisition Integration: Assess the integration progress and revenue contribution of the obp Surgical and Cook Medical assets.
- Debt Servicing: Review the impact of variable interest rates on the $2.5 billion debt portfolio, despite current hedging strategies.
- Foreign Exchange Sensitivity: Evaluate the volatility of the Euro and other currencies against the USD and its impact on the 60%+ of sales generated outside the U.S.